Qualigen Therapeutics ( NASDAQ: QLGN ) announced that on September 23, 2024, Michael Poirier, notified the board of directors of his intention to resign as Chief Executive Officer and Chairman of the Board, effective immediately. On the same date, Christopher Lotz, Chief Financial Officer also.
Back to Health Page
